

Adela RodrÃ-iguez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4741109/publications.pdf>

Version: 2024-02-01

14
papers

330
citations

1307366

7
h-index

1281743

11
g-index

14
all docs

14
docs citations

14
times ranked

590
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	2.2	175
2	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. <i>Annals of Oncology</i> , 2018, 29, 2121-2128.	0.6	74
3	Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2019, 173, 166-171.	0.8	32
4	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021, 7, 8.	2.3	14
5	Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism. <i>Thrombosis Research</i> , 2018, 171, 74-80.	0.8	11
6	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 303.	1.3	8
7	Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e210-e217.	0.7	7
8	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. <i>Cancers</i> , 2020, 12, 1124.	1.7	5
9	Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 551-558.	1.0	2
10	Mural thrombus of ascending aorta successfully managed with anticoagulation in a patient with metastatic cancer. <i>Thrombosis Research</i> , 2018, 164, S222-S223.	0.8	1
11	Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?. <i>Journal of Clinical Medicine</i> , 2021, 10, 746.	1.0	1
12	NOLUS: a predictive model to identify Basal-like and HER2-enriched intrinsic subtypes based on estrogen receptor (ER), progesterone receptor (PR) and Ki67 immunohistochemistry (IHC) in hormone receptor-positive/HER2-negative (HR+/HER2 ⁻) breast cancer (BC). <i>European Journal of Cancer</i> , 2018, 92, S138.	1.3	0
13	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3076-3076.	0.8	0
14	Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience.. <i>Journal of Clinical Oncology</i> , 2020, 38, 560-560.	0.8	0